DDInter1191 DDInter1658
Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Methylprednisolone {u} (Compound) resembles {v} (Compound) Halobetasol Propionate
Methylprednisolone {u} (Compound) resembles {v} (Compound) Testolactone
Methylprednisolone {u} (Compound) treats {v} (Disease) rheumatoid arthritis
Methylprednisolone {u} (Compound) binds {v} (Gene) CYP3A4
Methylprednisolone {u} (Compound) upregulates {v} (Gene) ZFP36
Methylprednisolone {u} (Compound) palliates {v} (Disease) hematologic cancer
Methylprednisolone {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Methylprednisolone {u} (Compound) downregulates {v} (Gene) FOSL1
Methylprednisolone {u} (Compound) causes {v} (Side Effect) Diplegia
Methylprednisolone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Isoniazid
Methylprednisolone (Compound) resembles Halobetasol Propionate (Compound)
Methylprednisolone (Compound) resembles Testolactone (Compound)
Methylprednisolone (Compound) treats rheumatoid arthritis (Disease)
Methylprednisolone (Compound) binds CYP3A4 (Gene)
Methylprednisolone (Compound) upregulates ZFP36 (Gene)
Methylprednisolone (Compound) palliates hematologic cancer (Disease)
Methylprednisolone (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Methylprednisolone (Compound) downregulates FOSL1 (Gene)
Methylprednisolone (Compound) causes Diplegia (Side Effect)
Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Isoniazid